AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04391595
Drug: Abemaciclib
RxNorm normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
Trial: NCT01200355
Drug: micafungin
RxNorm normalized name: Micafungin
DrugBank: Micafungin (DB01141)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
Trial: NCT01200355
Drug: posaconazole
RxNorm normalized name: Posaconazole
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
Trial: NCT00207090
Drug: ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression
Trial: NCT00207090
Drug: Rifampin
RxNorm normalized name: Rifampin
DrugBank: Rifampin (DB01045)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2
Trial: NCT03206008
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01157975
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone will be taken at a dose of 30 mg for up to 14 days
Trial: NCT01157975
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone will be taken at a dose of 40 mg for up to 4 days
Trial: NCT00309309
Drug: Rosiglitazone
RxNorm normalized name: Rosiglitazone
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00574275
Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.
Trial: NCT00574275
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m\^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
Trial: NCT02641821
Drug: Nifedipine GITS
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00689832
Drug: Tacrolimus 0.03%
RxNorm normalized name: TACROLIMUS 0.03% OINT,TOP
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ointment
Trial: NCT00689832
Drug: Fluticasone 0.005%
DrugBank: Fluticasone (DB13867)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ointment
Trial: NCT02045472
Drug: VIS410
RxNorm normalized name: IMMUNOGLOBULIN G1, ANTI-(INFLUENZA HEMAGGLUTININ) (HUMAN MONOCLONAL VIS410 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL VIS410 .KAPPA.-CHAIN, DIMER
DrugBank: VIS-410 (DB19067)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00644774
Drug: cefdinir (Omnicef)
RxNorm normalized name: Cefdinir
DrugBank: Cefdinir (DB00535)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
Trial: NCT01709513
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atorvastatin over-encapsulated tablets.
Trial: NCT01709513
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ezetimibe over-encapsulated tablet.
Trial: NCT01709513
Drug: Alirocumab
RxNorm normalized name: Alirocumab
DrugBank: Alirocumab (DB09302)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Alirocumab SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
Trial: NCT00129168
Drug: Zosuquidar
RxNorm normalized name: Zosuquidar
DrugBank: Zosuquidar (DB06191)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00129168
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00129168
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03070119
Drug: Tofersen
RxNorm normalized name: Tofersen
DrugBank: Tofersen (DB14782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a loading dose regimen followed by maintenance dosing.
Trial: NCT04442945
Drug: ANAVEX3-71
RxNorm normalized name: ANAVEX3-71
DrugBank: AF-710B (DB16911)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active oral dose of ANAVEX3-71
Trial: NCT01786096
Drug: SGN-CD19A
RxNorm normalized name: Moab, chimeric, SGN-30, to CD30 antigen
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
Trial: NCT05806853
Drug: 68Ga-PSMA
RxNorm normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glu-NH-CO-NH-Lys-(Ahx)-\[68Ga(HBED-CC)\] (68Ga-PSMA)
Trial: NCT05806853
Drug: 68Ga-RM2
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bombesin receptor antagonist (68Ga-RM2)
Trial: NCT02268903
Drug: Diuretics : Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide 80mg in one single direct intra venous injection
Trial: NCT00645593
Drug: Gemcitabine,
RxNorm normalized name: Gemcitabine, 38 mg/mL intravenous solution
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.
Trial: NCT00645593
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.
Trial: NCT00645593
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
Trial: NCT03350295
Drug: Nifurtimox (Lampit, BAYA2502)
RxNorm normalized name: nifurtimox
DrugBank: Nifurtimox (DB11820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Intake of 4 x 30 mg nifurtimox tablets for treatment A-C; Oral Intake of 1 x 30 mg nifurtimox tablets for treatment D Oral intake of 1 x 120 mg nifurtimox tablet for treatment E
Trial: NCT00102973
Drug: TLK286 in Combination with Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Experimental Arm
Trial: NCT03970447
Drug: Temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage Form: Capsule for oral administration Strengths: 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg
Trial: NCT03970447
Drug: Lomustine
RxNorm normalized name: Lomustine
DrugBank: Lomustine (DB01206)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage Form: Capsule for oral administration Strength: 5 mg, 10 mg, 40 mg, and 100 mg
Trial: NCT03970447
Drug: Regorafenib
RxNorm normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dosage Form: Tablet for oral administration Strength: 40 mg Standard Regimen: 160 mg orally (PO) every day (QD) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
Trial: NCT03970447
Drug: Paxalisib
RxNorm normalized name: Paxalisib
DrugBank: Paxalisib (DB15186)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage Form: Tablet for oral administration Strength: 15 mg Standard Regimen: 45 mg orally (PO) every day for 28 days for the first cycle. If tolerated, increase dose to 60 mg orally (PO) every day for 28 days for all subsequent cycles
Trial: NCT03970447
Drug: VAL-083
RxNorm normalized name: Val
DrugBank: Valine (DB00161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage Form: Infusion for intravenous administration Strength: 40 mg per vial Standard Regimen: 30 mg/m2 on Day 1, 2 and 3 of 21-day cycle. The drug is available in powder form. It is reconstituted with 5 mL of 0.9% Sodium Chloride for Injection, USP. This will produce a solution of 40 mg VAL-083 in 5 mL. The required volume of reconstituted VAL-083 for the patient is then calculated at the rate of 30 mg/m2. The corresponding volume is further diluted into 250 mL of 0.9% Sodium Chloride for Injection, USP, prior to intravenous administration.
Trial: NCT03970447
Drug: Troriluzole
RxNorm normalized name: Troriluzole
DrugBank: Troriluzole (DB15079)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage Form: Capsule for oral administration Strength: 100 mg Standard Regimen: Dose as confirmed through the dose finding phase orally BID.
Trial: NCT04574583
Drug: SX-682
RxNorm normalized name: SX-682
DrugBank: SX-682 (DB19210)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SX-682 will be given orally at designated dose twice a day every day
Trial: NCT03810703
Drug: d-amphetamine 20 mg oral capsule
RxNorm normalized name: dextroamphetamine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: d-amphetamine 20 mg oral capsule
Trial: NCT03686033
Drug: E2082
RxNorm normalized name: Ethinylestradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive E2082 tablets orally.
Trial: NCT01045161
Drug: Aclidinium bromide
RxNorm normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aclidinium bromide 200 μg, oral inhalation twice per day 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks of treatment.
Trial: NCT01911676
Drug: PF-03463275
RxNorm normalized name: PF-03463275
DrugBank: PF-03463275 (DB11993)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00280644
Drug: Leflunomide
RxNorm normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01970371
Drug: plazomicin
RxNorm normalized name: plazomicin
DrugBank: Plazomicin (DB12615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01970371
Drug: colistin
RxNorm normalized name: Colistin
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00925119
Drug: Atenolol
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12.5 mg twice daily of atenolol for 1 week; increased to 25 mg twice daily for a total of 8 weeks, if the medication is well tolerated
Trial: NCT00294437
Drug: Zometa
RxNorm normalized name: Zometa
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
Trial: NCT04445311
Drug: Ivermectin
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 successive days ttt of ivermectin started within 48 hours of symptoms
Trial: NCT03344952
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Repeated injections to hypertonic muscles
Trial: NCT01970371
Drug: meropenem
RxNorm normalized name: Meropenem
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01469351
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes.~Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation.~Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen.~1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used.
Trial: NCT01469351
Drug: non-active study drug
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00870441
Drug: Valacyclovir
RxNorm normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT02691442
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block
Trial: NCT02691442
Drug: Levobupivacaine 0.5%
RxNorm normalized name: levobupivacaine 0.5% injectable solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block
Trial: NCT02691442
Drug: Levobupivacaine 0.5% + epinephrin 1/200000
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block
Trial: NCT01541475
Drug: Bupropion, Escitalopram
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg
Trial: NCT01541475
Drug: Escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg
Trial: NCT01624662
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Delivered via Optinose Exhalation Delivery System
Trial: NCT02695459
Drug: cisplatinum and everolimus
RxNorm normalized name: Everolimus
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
Trial: NCT02351505
Drug: Selinexor
RxNorm normalized name: Selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given PO
Trial: NCT01582425
Drug: Isavuconazole
RxNorm normalized name: Isavuconazole
DrugBank: Isavuconazole (DB11633)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT01582425
Drug: Methadone
RxNorm normalized name: Methadone
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT04458298
Drug: OP-101
RxNorm normalized name: OP-101
DrugBank: Acetylcysteine zidrimer (DB16496)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OP-101 infusion will be administered intravenously.
Trial: NCT02596100
Drug: Betrixaban
RxNorm normalized name: Betrixaban
DrugBank: Betrixaban (DB12364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01960374
Drug: Selumetinib
RxNorm normalized name: SELUMETINIB
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1, 2 or 3 x 25 mg selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) capsule administered orally as a single dose on Day 1 of the study (total dose 25 mg, 50 mg and 75 mg respectively) with 240 ml of water at room temperature.
Trial: NCT01353664
Drug: Romidepsin
RxNorm normalized name: Romidepsin
DrugBank: Romidepsin (DB06176)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.
Trial: NCT00987103
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral: 0,1 mg/kg Rectal: 15 mg Sublingual: 0,04 mg/kg
Trial: NCT01001403
Drug: Nafamostat
RxNorm normalized name: Nafamostat
DrugBank: Nafamostat (DB12598)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: 0.2 mg/kg as bolus 1 minute before reperfusion
Trial: NCT03994172
Drug: Teriparatide or human parathyroid hormone (PTH) 1-34
RxNorm normalized name: Parathyroid hormone (1-84) human recombinant
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Teriparatide or PTH 1-34 is a 34 amino acid peptide derived by recombinant DNA technology from the authentic sequence of human parathyroid hormone. It is given by subcutaneous injection in the dosage of 20 micrograms per day in the trial in both treatment arms for the 48 weeks or 11 months of the trial.
Trial: NCT03994172
Drug: Cinacalcet
RxNorm normalized name: Cinacalcet
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This drug is an orally active calcimimetic (drug that activates Ca-sensing receptors on target cells) that will be given daily orally to the men randomized to the Experimental Treatment Arm (#1). Cinacalcet tablets will be given simultaneously with the injection of PTH(1-34) or teriparatide. Cinacalcet will be given only once daily but given every single day of the trial starting with the Randomization Visit for the duration of 48 weeks or 11 months of the trial.
Trial: NCT03715881
Drug: Intravenous Erythropoietin injection
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 units of erythropoietin every 12 hours for three days
Trial: NCT00844753
Drug: atomoxetine
RxNorm normalized name: Atomoxetine
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atomoxetine
Trial: NCT02142777
Drug: S -Equol
RxNorm normalized name: equol, (+-)-
DrugBank: Equol (DB11674)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We will determine if the intervention (S-equol) alters platelet mitochondria COX activity.
Trial: NCT00510926
Drug: Imatinib Mesilate (Glivec)
RxNorm normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01648127
Drug: Ceftaroline
RxNorm normalized name: Ceftaroline
DrugBank: Ceftaroline fosamil (DB06590)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion
Trial: NCT00165685
Drug: Sibutramine Hydrochloride Monohydrate
RxNorm normalized name: sibutramine hydrochloride monohydrate
DrugBank: Sibutramine (DB01105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00770367
Drug: Pioglitazone then Placebo
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take the pioglitazone 30mg tablet daily for 3 months. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take a placebo.
Trial: NCT00770367
Drug: Placebo then Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take the placebo for the first 12 weeks of the study. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take the pioglitazone 30mg tablet daily for 3 months.
Trial: NCT02446431
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avastin is an anti-angiogenic therapy that disrupts a tumor's ability to grow by blocking the vascular endothelial growth factor protein, or VEGF. In tumors, cells produce excess VEGF therefore avastin's ability to block VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors. Avastin is not a chemotherapy; the purpose of Avastin is to block the blood supply that feeds the tumor. In this study Avastin is given IV at 10 mg/kg twice monthly for 10 cycles. This totals 20 administrations over a 1.12 year period.
Trial: NCT02446431
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Valproic acid is a short chain fatty acid (VPA, 2-propylpetanoic acid) and approved for the treatment of epilepsy, bipolar disorders, migraines, and clinically used for schizophrenia. Currently, VPA is examined in numerous clinical trials for different leukemias and solid tumor entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. Valproic acid is either given in suspension or tablet form 5 mg/kg, TID for 13 days for 10 cycles. This totals 130 days in a 1.12 year period.